Skip to main content

Table 1 Basic characteristics of included studies

From: Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis

Author, year Country No. Stage Follow-up Preoperative chemoradiotherapy Curative surgical resection Postoperative adjuvant chemotherapy no. PD-L1 (%) HR Cutoff for positive
Enkhbat, 2018 [15] Japan 116 II–III 52 months (mean) NA YES 57 52/116 3.873 Score > 3 (intensity + area)
Masugi, 2016 [35] America 450 I–IV > 5 years NA YSE NA 121/450 1.124 Score = 1 (intensity)
117/450 0.980 Score = 2 (intensity)
139/450 1.042 Score = 3 (intensity)
26/450 1.370 Score = 4 (intensity)
Saigusa, 2016 [16] Japan 90 I–IV > 6 months YES YES 90 36/90 2.452 Score ≥ 2 (intensity)
Zhu, 2015 [36] China 120 NA 39 months (mean) NA YES NA 28/120 0.692 Score > 4 (intensity + area)
Liang, 2014 [17] China 185 I–IV > 5 years NA YES NA 102/185 1.740 Score > 4 (intensity + area)
Droeser, 2014 [37] Switzerland 1420 NA > 5 years NA YES NA 495/1420 0.92 Subjective evaluation
Hamada, 2017 [20] America 384 I–IV > 5 years NA YES NA 211/384 1.20 Score ≥ 2 (intensity + area)
Lee, 2018 [18] Korea 336 I–IV 52 months (mean) NA YES NOT 15/336 3.785 Area > 1%
Li, 2016 [19] China 276 NA 61 months (mean) NA YES 189 138/276 1.048 Score > 4 (intensity + area)
Miller, 2017 [38] Australia 104 III 82.5 months (mean) NA YES 89 60/104 1.00 Subjective evaluation
  1. NA not available, NOT no patients underwent, mean average follow-up time is provided only, intensity + area the score involved staining intensity and staining range, intensity the score involved staining intensity only